The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.
A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state. | A Minnesota analysis of providers' reported ...
A new Ohio bill won't expand the 340B program, but it will protect patients' ability to fill prescriptions at their pharmacy of choice.
On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...
The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...
Opinion
AHA Comments on HRSA’s RFI Re: 340B Rebate Model Pilot Program – HHS Docket No. HRSA-2026-03042
The American Hospital Association's initial comment on the Health Resources and Services Administration’s (HRSA) request for information regarding a 340B Rebate Model Pilot Program.
Add Yahoo as a preferred source to see more of our stories on Google. Photo: Shopify Partners / Burst (The Center Square) – Hospitals and clinics in Michigan participating in a federal drug discount ...
The 340B Drug Pricing Program was originally constructed so safety-net health care facilities could stretch scarce resources in caring for low-income patients. However, the program has experienced ...
The 340B Drug Pricing Program was created in 1992 and allows hospitals and clinics that treat a large population of low-income and uninsured patients to buy outpatient prescription drugs at a discount ...
The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...
Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results